Liver health may change how body handles inhaled lung drug

NCT ID NCT07643155

Recruiting now Knowledge-focused Sponsor: Insmed Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This phase 1 trial investigates how mild, moderate, and severe liver impairment affects the way the body processes a single inhaled dose of treprostinil palmitil, a drug used for certain lung conditions. The study enrolls about 30 adults with varying levels of liver function and measures drug levels in the blood over time. The goal is to understand if liver problems require dose adjustments, not to test the drug's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: treprostinil palmitil inhalation powder
What this could lead to: If successful, this study could help doctors determine safe dosing of treprostinil palmitil for people with liver problems.
What could go wrong: This is a small, early-phase trial focused on drug processing, not treatment effectiveness. Results may not apply to all patients or lead to changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Orange Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
Orlando County Research Center
RECRUITING

Lake Forest, California, 92630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.